Fibromyalgia K. Mukhida Department of Anesthesiology, Pain - - PowerPoint PPT Presentation

fibromyalgia
SMART_READER_LITE
LIVE PREVIEW

Fibromyalgia K. Mukhida Department of Anesthesiology, Pain - - PowerPoint PPT Presentation

Fibromyalgia K. Mukhida Department of Anesthesiology, Pain Management and Perioperative Medicine Dalhousie University February 2019 Disclosures None Objectives At the end of this session you will be able to: Assess a patient with CWP


slide-1
SLIDE 1

Fibromyalgia

  • K. Mukhida

Department of Anesthesiology, Pain Management and Perioperative Medicine Dalhousie University February 2019

slide-2
SLIDE 2

Disclosures

  • None
slide-3
SLIDE 3

Objectives

At the end of this session you will be able to:

  • Assess a patient with CWP and know the diagnostic criteria for

fibromyalgia

  • Come up with a differential diagnosis for CWP
  • Come up with management options for the patient with

fibromyalgia

slide-4
SLIDE 4
  • Nociceptive: damage (trauma, inflammation)
  • Neuropathic: nerves
  • Centralized: neuronal dysregulation, overactive pain pathways,

deficiency of descending inhibitory pain pathways

Hauser W and Fitzcharles M-A (2018). Dialogues Clin Neurosci 20: 53-61. Atzeni F et al. (2017). Expert Opinion on Emerging Drugs 22: 357-367.

slide-5
SLIDE 5

CL is a 56 year old woman who is new to your practice. She tells you that she is coming to see you because she has pain “all over.”

slide-6
SLIDE 6

History PMH FMH Social Physical examination Investigations

slide-7
SLIDE 7

Arnold LM et al. (2018). The Journal of Pain https://doi.org/10.1016/j.pain.2018.10.008.

slide-8
SLIDE 8

PAIN FATIGUE SLEEP DISTURBANCES COGNITIVE PROBLEMS

slide-9
SLIDE 9

Clauw DJ (2014). JAMA 311: 1547-1555.

slide-10
SLIDE 10
  • Widespread pain index: at least 7

AND Symptom severity score: at least 5 OR WPI 4-6 AND SSS over 9

  • Diagnosis is valid irrespective of other diagnoses

Wolfe F et al. (2016). Seminars in Arthritis and Rheumatism 46: 319-329.

slide-11
SLIDE 11

What is in your differential diagnosis for CL’s pain?

slide-12
SLIDE 12

Inflammatory rheumatic diseases Nonrheumatic msk conditions Nonrheumatic medical conditions Neurological conditions Mental health disorders Medication-induced pain conditions

Hauser W et al. (2018). Pain Reports e958.

slide-13
SLIDE 13

Inflammatory rheumatic diseases

Symptoms: joint swelling Examples: SLE, RA, Sjogren, scleroderma, inflammatory polyarthritis, PMR, inflammatory spondyloarthritis Red flags: FHx, am stiffness > 1 hr, severe constitutional symptoms

Hauser W et al. (2018). Pain Reports e958.

slide-14
SLIDE 14

Inflammatory rheumatic diseases Nonrheumatic msk conditions

Symptoms: trigger points Examples: myofascial pain syndrome, CTDs Red flags: pronounced neck and shoulders

Hauser W et al. (2018). Pain Reports e958.

slide-15
SLIDE 15

Inflammatory rheumatic diseases Nonrheumatic msk conditions Nonrheumatic medical conditions

Endocrine / metabolic: hypothyroidism, hyperparathyroidism, acromegaly GI: celiac disease ID: Lyme disease, hepatitis C, HIV

Hauser W et al. (2018). Pain Reports e958.

slide-16
SLIDE 16

Inflammatory rheumatic diseases Nonrheumatic msk conditions Nonrheumatic medical conditions Neurological conditions

Examples: MS, PD, peripheral neuropathies, myelopathy, myopathies

Hauser W et al. (2018). Pain Reports e958.

slide-17
SLIDE 17

Medication-induced pain conditions

Statins Opioids Chemotherapy Aromatase inhibitors bisphosphonates

Hauser W et al. (2018). Pain Reports e958.

slide-18
SLIDE 18

P P P P

Physical

Psychological

Pins

Pharmacological

*

slide-19
SLIDE 19
  • Exercise
  • Meditative movement therapies
  • Dance

Arnold LM & Clauw DJ (2017). Postgraduate Medicine 129: 709-714. Bidonde J et al. (2017). Cochrane Database of Systematic Reviews 6: CD012700. Gota CE (2018). Cleveland Clinic Journal of Medicine 85: 367-376. Honda Y et al. (2018). Pain Research & Management https://doi.org/10.1155/2018/2930632. Murillo-García et al. (2018). Evidence-based Complementary and Alternative Medicine 8709748. Sosa-Reina MD et al. (2017). BioMed Research International 2356346. Sawynok J & Lynch M (2017). Medicines 4: 37.

slide-20
SLIDE 20

Overview of recommended treatment strategies:

Pharmacological management

Level of evidence Strength of recommendation

Amitriptyline 1 (weak for) A Anticonvulsants 1 (weak for) A Muscle relaxant

  • SNRIs

1 (weak for) A SSRIs 1 (weak for) A multicomponent therapy 5 D

Arnold LM & Clauw DJ (2017). Postgraduate Medicine 129: 709-714. Fitzcharles MA et al. (2012). Pain Research and Management 18: 119-126. Macfarlane GJ et al. (2017). Annals of Rheumatologic Disease 76: 318-328.

slide-21
SLIDE 21
  • Not responsive to injections
slide-22
SLIDE 22
  • CBT

Aman MM et al. (2018). Current Pain and Headache Reports 22: 33. Bernardy K et al. (2017). European Journal of Pain 22: 242-260. Bernardy K et al. (2018). European Journal of Pain doi: 10.1002/ejp.1284. Mehta S et al. (2018). Journal of Behavioral Medicine https://doi.org/10/1007/s10865-018-9984-x

slide-23
SLIDE 23

Overview of recommended treatment strategies:

Nonpharmacological management

Level of evidence Strength of recommendation

Aerobic exercise 1 (strong for) A Balneotherapy

  • Cognitive behavioural therapy

1 (weak for) A Defined physical therapies 1 (weak for) A Meditative movement therapies 1 (weak for) A Mindfulness-based stress reduction

  • Strengthening exercise

1 (strong for) A

Arnold LM & Clauw DJ (2017). Postgraduate Medicine 129: 709-714. Fitzcharles MA et al. (2012). Pain Research and Management 18: 119-126. Macfarlane GJ et al. (2017). Annals of Rheumatologic Disease 76: 318-328.

slide-24
SLIDE 24

Confirm diagnosis:

  • ID important symptom domains / level of function
  • Evaluate for comorbid medical / psychiatric disorders
  • Assess psychosocial stressors, level of fitness, barriers to treatment
  • Provide education about FM

Recommend individualized treatment Nonpharmacological therapy:

  • CBT
  • Exercise

Pharmacological therapy: Depression

  • SNRI

Sleep

  • ⍺2d ligand

Partial response monotherapy

  • ⍺2d ligand +/- SNRI +/- TCA

Arnold LM & Clauw DJ (2017). Postgraduate Medicine 129: 709-714.